Observational studyJournal of global oncology2019
Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Observational study in Journal of global oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 4 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Prevalence of hematological malignancies in Africa: A systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Low-Bacterial Diet in Cancer Patients: A Systematic Review.Nutrients · 2023Pooled it
- Smartphone Apps for Patients With Hematologic Malignancies: Systematic Review and Evaluation of Content.JMIR mHealth and uHealth · 2022Pooled it
- Patient Perceived Financial Burden in Haematological Malignancies: A Systematic Review.Current oncology (Toronto, Ont.) · 2022Pooled it
- Sleep quality and sleepiness in adults with multiple myeloma. Is melatonin a potential treatment?Physiological reports · 2026Observational
- Unveiling economic and humanistic burden of hematologic malignancies in Japan with personal health record data.Scientific reports · 2026Article
- Early Palliative Care in Advanced Hematologic Malignancies: A Systematic Review of Patient-Centered Outcomes.Healthcare (Basel, Switzerland) · 2025Review
- Perceptions and Needs of Stakeholders Regarding MyPal Project's Electronic Patient-Reported Outcome App: Cross-Sectional Qualitative Focus Group Study.JMIR cancer · 2025Article
- Review
- Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study.International journal of hematology · 2025Article
- Phase 2 trial of daratumumab, cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma.Blood neoplasia · 2025Article
- Usability and User Experience Testing of a Co-Designed Electronic Patient-Reported Outcomes App ("MyPal for Adults") for Palliative Cancer Care: Mixed Methods Study.JMIR human factors · 2025Article
- Clinical characteristics, treatment patterns and outcomes of patients with follicular lymphoma in Colombia: a real-world evidence cohort study.Annals of hematology · 2025Article
- Health care systems as determinants of outcomes in multiple myeloma: final results from the Latin American MYLACRE study.Blood advances · 2025Observational
- Oral ulcers in hematological malignancy patients undergoing chemotherapy: is it chemotherapy or neutropenia?: a case report and review of the literature.Journal of medical case reports · 2025Review
- Article
- TIMAP downregulation in Burkitt's lymphoma reveals key molecules and signaling pathways in B-cell lymphomagenesis.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Common haematological malignancies in Northeastern Nigeria: a multi-centre study of their pattern, distribution and treatment challenges.Frontiers in oncology · 2025Article
- Autologous stem cell transplantation in patients older than 65 years with multiple myeloma: a real-world study.Hematology, transfusion and cell therapy · 2024Article
- Psychological burden and depressive symptoms in caregivers of hemato-oncological patients: the role of medical visits.Blood advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 20 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLimited information is available on multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) management in Latin America. The primary objective of the Hemato-Oncology Latin America (HOLA) study was to describe patient characteristics and treatment patterns of Latin American patients with MM, CLL, and NHL.
methodsThis study was a multicenter, retrospective, medical chart review of patients with MM, CLL, and NHL in Latin America identified between January 1, 2006, and December 31, 2015. Included were adults with at least 1 year of follow-up (except in cases of death within 1 year of diagnosis) treated at 30 oncology hospitals (Argentina, 5; Brazil, 9; Chile, 1; Colombia, 5; Mexico, 6; Panama/Guatemala, 4).
resultsOf 5,140 patients, 2,967 (57.7%) had NHL, 1,518 (29.5%) MM, and 655 (12.7%) CLL. Median follow-up was 2.2 years for MM, 3.0 years for CLL, and 2.2 years for NHL, and approximately 26% died during the study observation period. Most patients had at least one comorbidity at diagnosis. The most frequent induction regimen was thalidomide-based chemotherapy for MM and chlorambucil with or without prednisone for CLL. Most patients with NHL had diffuse large B-cell lymphoma (DLBCL; 49.1%) or follicular lymphoma (FL; 19.5%). The majority of patients with DLBCL or FL received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
conclusionThe HOLA study generated an unprecedented level of high-quality, real-world evidence on characteristics and treatment patterns of patients with hematologic malignancies. Regional disparities in patient characteristics may reflect differences in ethnoracial identity and level of access to care. These data provide needed real-world evidence to understand the disease landscape in Latin America and may be used to inform clinical and health policy decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.